WO2001083794A3 - Dna transfection system for the generation of infectious influenza virus - Google Patents

Dna transfection system for the generation of infectious influenza virus Download PDF

Info

Publication number
WO2001083794A3
WO2001083794A3 PCT/US2001/013656 US0113656W WO0183794A3 WO 2001083794 A3 WO2001083794 A3 WO 2001083794A3 US 0113656 W US0113656 W US 0113656W WO 0183794 A3 WO0183794 A3 WO 0183794A3
Authority
WO
WIPO (PCT)
Prior art keywords
rna
attenuated
viruses
influenza virus
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/013656
Other languages
French (fr)
Other versions
WO2001083794A2 (en
Inventor
Erich Hoffmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
St Jude Childrens Research Hospital
Original Assignee
St Jude Childrens Research Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to HK03107765.5A priority Critical patent/HK1055992B/en
Priority to DE60137345T priority patent/DE60137345D1/en
Priority to NZ521840A priority patent/NZ521840A/en
Priority to AU5921101A priority patent/AU5921101A/en
Priority to IL152426A priority patent/IL152426A/en
Priority to DK01932704T priority patent/DK1317559T3/en
Priority to JP2001580401A priority patent/JP2004500842A/en
Priority to CA2406100A priority patent/CA2406100C/en
Priority to MXPA02010642A priority patent/MXPA02010642A/en
Priority to AU2001259211A priority patent/AU2001259211B2/en
Priority to UA2002108499A priority patent/UA84254C2/en
Application filed by St Jude Childrens Research Hospital filed Critical St Jude Childrens Research Hospital
Priority to DE201112100039 priority patent/DE122011100039I1/en
Priority to HU0303036A priority patent/HU229101B1/en
Priority to SI200130900T priority patent/SI1317559T1/en
Priority to EP01932704A priority patent/EP1317559B1/en
Priority to EA200201164A priority patent/EA006311B1/en
Priority to BRPI0110607-4 priority patent/BRPI0110607B8/en
Publication of WO2001083794A2 publication Critical patent/WO2001083794A2/en
Priority to NO20025171A priority patent/NO332080B1/en
Anticipated expiration legal-status Critical
Publication of WO2001083794A3 publication Critical patent/WO2001083794A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/00061—Methods of inactivation or attenuation
    • C12N2720/00063—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16163—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16261—Methods of inactivation or attenuation
    • C12N2760/16263—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18661—Methods of inactivation or attenuation
    • C12N2760/18663—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24261—Methods of inactivation or attenuation
    • C12N2770/24263—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/40—Systems of functionally co-operating vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • C12N2830/205—Vector systems having a special element relevant for transcription transcription of more than one cistron bidirectional
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/34—Vector systems having a special element relevant for transcription being a transcription initiation element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/36—Vector systems having a special element relevant for transcription being a transcription termination element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is based on the development of a dual promoter system (preferably a RNA pol I -pol II system) for the efficient intracellular synthesis of viral RNA. The resultant minimal plasmid-based system may be used to synthesize any RNA virus, preferably viruses with a negative single stranded RNA genome. The viral product of the system is produced when the plasmids of the system are introduced into a suitable host cell. One application of the system is production of attenuated, reassortant influenza viruses for use as antigens in vaccines. The reassortant viruses generated by cotransfection of plasmids may comprise genes encoding the surface glycoproteins hemagglutinin and neuraminidase from an influenza virus currently infecting the population and the internal genes from an attenuated influenza virus. An advantageous property of the present invention is its versatility; the system may be quickly and easily adapted to synthesize an attenuated version of any RNA virus. Attenuated or inactivated RNA viruses produced by the present invention may be administered to a patient in need of vaccination by any of several routes including intranasally or intramuscularly.
PCT/US2001/013656 2000-04-28 2001-04-27 Dna transfection system for the generation of infectious influenza virus Ceased WO2001083794A2 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
UA2002108499A UA84254C2 (en) 2000-04-28 2001-04-27 THE MINIMAL PLASMID-BASED SYSTEM FOR GENERATION OF INFECTIOUS NEGATIVE STRANDED RNA OF VIRUSES FROM THE CLONED VIRUS cDNA, THE HOST CELL, CONTAINING THE PLASMID-BASED SYSTEM, THE METHOD FOR PRODUCTION OF INFECTIOUS NEGATIVE STRANDED RNA OF VIRUS AND THE METHOD FOR VACCINATION OF A PERSON AGAINST INFECTION OF NEGATIVE STRANDED RNA VIRUS
NZ521840A NZ521840A (en) 2000-04-28 2001-04-27 Development of a multi-plasmid pol I - pol II based system for the generation of infectious influenza RNA viruses from cloned DNA
AU5921101A AU5921101A (en) 2000-04-28 2001-04-27 Dna transfection system for the generation of infectious influenza virus
IL152426A IL152426A (en) 2000-04-28 2001-04-27 Dna transfection system for the generation of infectious negative strand rna virus
DK01932704T DK1317559T3 (en) 2000-04-28 2001-04-27 DNA transfection system to produce infectious negative-stranded RNA virus
JP2001580401A JP2004500842A (en) 2000-04-28 2001-04-27 Transfection system for the generation of infectious influenza virus
DE201112100039 DE122011100039I1 (en) 2000-04-28 2001-04-27 DNA transfection system for the generation of infectious negative-stranded RNA virus.
DE60137345T DE60137345D1 (en) 2000-04-28 2001-04-27 DNA TRANSFECTION SYSTEM FOR GENERATING INFECTIOUS NEGATIVE RNA RNA
AU2001259211A AU2001259211B2 (en) 2000-04-28 2001-04-27 DNA transfection system for the generation of infectious influenza virus
HK03107765.5A HK1055992B (en) 2000-04-28 2001-04-27 Dna transfection system for the generation of infectious negative strand rna virus
MXPA02010642A MXPA02010642A (en) 2000-04-28 2001-04-27 Dna transfection system for the generation of infectious influenza virus.
CA2406100A CA2406100C (en) 2000-04-28 2001-04-27 Dna transfection system for the generation of infectious influenza virus
HU0303036A HU229101B1 (en) 2000-04-28 2001-04-27 Dna transfection system for the generation of infectious influenza virus
SI200130900T SI1317559T1 (en) 2000-04-28 2001-04-27 Dna transfection system for the generation of infectious negative strand rna virus
EP01932704A EP1317559B1 (en) 2000-04-28 2001-04-27 Dna transfection system for the generation of infectious negative strand rna virus
EA200201164A EA006311B1 (en) 2000-04-28 2001-04-27 Dna transfection system for the generation of infectious influenza virus
BRPI0110607-4 BRPI0110607B8 (en) 2000-04-28 2001-04-27 plasmid-based system, method for producing an RNA negative strand virus virion, method for producing an orthomyxoviridae virion, method for producing an influenza virion, method for producing a pathogenic influenza virion, method for preparing a specific negative strand RNA virus vaccine and method for generating an attenuated negative strand RNA virus
NO20025171A NO332080B1 (en) 2000-04-28 2002-10-28 Minimal plasmid-based system for producing infectious influenza virus, host cell, method of preparation and use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20067900P 2000-04-28 2000-04-28
US60/200,679 2000-04-28

Publications (2)

Publication Number Publication Date
WO2001083794A2 WO2001083794A2 (en) 2001-11-08
WO2001083794A3 true WO2001083794A3 (en) 2003-03-27

Family

ID=22742710

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/013656 Ceased WO2001083794A2 (en) 2000-04-28 2001-04-27 Dna transfection system for the generation of infectious influenza virus

Country Status (25)

Country Link
US (6) US6951754B2 (en)
EP (2) EP2085468A1 (en)
JP (3) JP2004500842A (en)
KR (2) KR100848719B1 (en)
CN (2) CN101580849B (en)
AT (1) ATE420189T1 (en)
AU (3) AU2001259211B2 (en)
BR (1) BRPI0110607B8 (en)
CA (1) CA2406100C (en)
CY (1) CY1108735T1 (en)
DE (2) DE122011100039I1 (en)
DK (1) DK1317559T3 (en)
EA (1) EA006311B1 (en)
ES (1) ES2319864T3 (en)
HU (1) HU229101B1 (en)
IL (1) IL152426A (en)
MX (1) MXPA02010642A (en)
NO (1) NO332080B1 (en)
NZ (1) NZ521840A (en)
PL (1) PL205955B1 (en)
PT (1) PT1317559E (en)
SI (1) SI1317559T1 (en)
UA (1) UA84254C2 (en)
WO (1) WO2001083794A2 (en)
ZA (1) ZA200208065B (en)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
MXPA02010642A (en) * 2000-04-28 2004-05-17 St Jude Children S Res Hospital Dna transfection system for the generation of infectious influenza virus.
US7465456B2 (en) * 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
ES2526191T3 (en) * 2002-04-26 2015-01-08 Medimmune, Llc Method to produce infectious influenza B virus in cell culture
EP1375670B1 (en) 2002-06-20 2013-06-12 Institut Pasteur Recombinant measles viruses expressing epitopes of antigens of RNA viruses and use of the recombinant viruses for the preparation of vaccine compositions
EP1375512B1 (en) 2002-06-20 2009-07-22 Institut Pasteur Infectious cDNA of an approved vaccine strain of measles virus. Use for immunogenic compositions
DE10248301A1 (en) * 2002-10-16 2004-04-29 Philipps-Universität Marburg Production of a live vaccine against influenza viruses
US7262045B2 (en) 2003-02-25 2007-08-28 Medimmune Vaccines, Inc. Methods of producing influenza vaccine compositions
US20060110406A1 (en) 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
CA2432738A1 (en) 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
KR20060026854A (en) * 2003-05-28 2006-03-24 위스콘신 얼럼나이 리서어치 화운데이션 Recombinant Influenza Vectors with PI2 Promoter and Ribozyme
AU2004249133B2 (en) * 2003-05-28 2009-05-28 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines and gene therapy
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
US7037707B2 (en) * 2003-09-04 2006-05-02 St. Jude Children's Research Hospital Method for generating influenza viruses and vaccines
ATE469972T1 (en) * 2003-12-23 2010-06-15 Medimmune Llc MULTIPLASMID SYSTEM FOR GENERATING THE FLU VIRUS
WO2005107797A1 (en) 2004-03-09 2005-11-17 Chiron Corporation Influenza virus vaccines
DE102004013335A1 (en) * 2004-03-17 2005-10-13 TransMIT Gesellschaft für Technologietransfer mbH Vaccine against influenza based on avian influenza viruses
US20090104226A1 (en) * 2004-05-21 2009-04-23 Novartis Vaccines And Diagnostics Inc. Alphavirus Vectors for Respiratory Pathogen Vaccines
EP2995678A1 (en) 2004-05-24 2016-03-16 MedImmune, LLC Multi plasmid system for the production of attenuated influenza b virus
CA2879182C (en) 2004-05-25 2017-02-14 Medimmune, Inc. Influenza hemagglutinin and neuraminidase variants
JP5147405B2 (en) 2004-10-06 2013-02-20 メディミューン，エルエルシー Refrigerated temperature stable influenza vaccine composition
CN101103103A (en) 2004-11-19 2008-01-09 威斯康星旧生研究基金会 Recombinant influenza virus vectors with tandem transcription units
ES2536745T3 (en) * 2004-12-08 2015-05-28 Medimmune, Llc Methods of production of influenza vaccine compositions
ATE547511T1 (en) 2004-12-23 2012-03-15 Medimmune Llc NON-TUMOR FORMING MDCK CELL LINE FOR REPRODUCTION OF VIRUSES
EP2295542B1 (en) * 2004-12-24 2013-01-30 Abbott Biologicals B.V. Rescue of influenza virus
EP2441471B1 (en) 2005-03-08 2014-10-08 MedImmune, LLC Reassortant influenza viruses
CA2606429A1 (en) * 2005-04-21 2006-11-02 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7790434B2 (en) 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
RU2008101367A (en) 2005-06-21 2009-08-10 Медиммун, Ллк (Us) METHODS AND COMPOSITIONS FOR EXPRESSION OF NEGATIVE SENSE VIRAL RNA IN DOGS CELLS
US8354114B2 (en) 2005-10-17 2013-01-15 Medimmune, Llc Multi plasmid system for the production of influenza virus
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
WO2007052061A2 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
EP1951298A1 (en) * 2005-11-04 2008-08-06 Novartis Vaccines and Diagnostics S.r.l. Adjuvanted influenza vaccines including cytokine-inducing agents
ES2420829T3 (en) 2005-11-04 2013-08-27 Novartis Vaccines And Diagnostics S.R.L. Vaccines adjuvant with non-virion antigen prepared from influenza viruses grown in cell culture
NZ568211A (en) 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
WO2007052059A2 (en) * 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Changing th1/th2 balance in split influenza vaccines with adjuvants
US20090304742A1 (en) 2005-11-04 2009-12-10 Novartis Vaccines And Diagnostics Srl Influenza vaccines with reduced amount of emulsion adjuvant
EP3753574A1 (en) 2006-01-27 2020-12-23 Seqirus UK Limited Influenza vaccines containing hemagglutinin and matrix proteins
EP2004226A1 (en) 2006-03-24 2008-12-24 Novartis Vaccines and Diagnostics GmbH & Co. KG Storage of influenza vaccines without refrigeration
WO2007126810A2 (en) * 2006-03-31 2007-11-08 Warf - Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
AU2014202470B2 (en) * 2006-03-31 2016-08-04 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
AU2012204138B2 (en) * 2006-03-31 2014-02-06 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
PT2016194E (en) 2006-04-19 2015-07-20 Medimmune Llc Methods and compositions for expressing negative-sense viral rna in canine cells
US9072701B2 (en) 2006-04-21 2015-07-07 St. Jude Children's Research Hospital Avian influenza viruses, vaccines, compositions, formulations, and methods
US7507411B2 (en) * 2006-06-23 2009-03-24 University Of Saskatchewan Attenuated influenza NS1 variants
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
WO2008133701A1 (en) * 2006-07-21 2008-11-06 Medimmune, Llc. Methods and compositions for increasing replication capacity of an influenza virus
EP2056872A4 (en) * 2006-08-09 2016-12-21 Medimmune Llc HEMAGGLUTININ AND NEURAMINIDASE VARIANTS OF FLU
ES2536401T3 (en) 2006-09-11 2015-05-25 Novartis Ag Making vaccines against influenza viruses without using eggs
WO2008105931A2 (en) 2006-09-15 2008-09-04 Medimmune Vaccines, Inc. Mdck cell lines supporting viral growth to high titers and bioreactor process using the same
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
SG177141A1 (en) 2006-12-06 2012-01-30 Novartis Ag Vaccines including antigen from four strains of influenza virus
US20130005028A1 (en) * 2006-12-21 2013-01-03 Smith Larry R Activation of RIG-I Pathway
WO2008153236A1 (en) * 2007-06-15 2008-12-18 Protheon Co., Ltd An attenuated influenza virus and a live vaccine comprising the same
CA2690196A1 (en) 2007-06-18 2008-12-24 Medimmune, Llc Influenza b viruses having alterations in the hemaglutinin polypeptide
WO2008156778A2 (en) 2007-06-18 2008-12-24 Tokiko Watanabe Influenza m2 protein mutant viruses as live influenza attenuated vaccines
EA201070066A1 (en) 2007-06-27 2010-06-30 Новартис Аг VACCINES AGAINST FLU WITH LOW CONTENT OF ADDITIVES
EP2045323A1 (en) * 2007-10-05 2009-04-08 Avir Green Hills Biotechnology Research Development Trade Ag Linear expression constructs for production of influenza virus particles
ES2447875T3 (en) 2007-10-02 2014-03-13 Theranos, Inc. Modular devices for care points and their uses
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
KR101718497B1 (en) 2007-11-26 2017-03-22 런던 스쿨 오브 하이진 앤 트로피컬 메디신 Method for producing vaccinal viral strain of a virus of the reoviridae family
WO2009115917A2 (en) 2008-03-18 2009-09-24 Novartis Ag Improvements in preparation of influenza virus vaccine antigens
WO2010006144A2 (en) * 2008-07-11 2010-01-14 Medlmmune, Llc. Influenza hemagglutinin and neuraminidase variants
CN102215865B (en) 2008-09-24 2013-10-30 米迪缪尼有限公司 Methods for purification of viruses
EP2233568A1 (en) 2009-03-19 2010-09-29 Avir Green Hills Biotechnology Research Development Trade AG Novel method for generation of RNA virus
WO2010092479A2 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccines with reduced amounts of squalene
SI2396030T1 (en) 2009-02-10 2015-12-31 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
AU2010212548A1 (en) 2009-02-10 2011-09-15 Novartis Ag Influenza vaccines with increased amounts of H3 antigen
CN102361649A (en) 2009-02-12 2012-02-22 米迪缪尼有限公司 Influenza hemagglutinin and neuraminidase variants
EP3009145A1 (en) 2009-03-30 2016-04-20 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
FR2949344A1 (en) 2009-04-27 2011-03-04 Novartis Ag FLU PROTECTIVE VACCINES
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
US9217157B2 (en) 2009-07-27 2015-12-22 Icahn School Of Medicine At Mount Sinai Recombinant influenza viruses and uses thereof
US8828406B2 (en) 2009-07-30 2014-09-09 Icahn School Of Medicine At Mount Sinai Influenza viruses and uses thereof
WO2011012999A1 (en) 2009-07-31 2011-02-03 Novartis Ag Reverse genetics systems
CN102695523A (en) 2009-09-10 2012-09-26 诺华有限公司 Combination vaccines against respiratory tract diseases
CN102741399A (en) * 2009-10-20 2012-10-17 诺华有限公司 Improved reverse genetics methods for virus rescue
EP2493912B1 (en) 2009-10-26 2020-07-29 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
CN102051345B (en) * 2009-11-09 2013-04-17 中国医学科学院医药生物技术研究所 Method for screening influenza virus resisting medicines
CA2790380A1 (en) * 2010-02-18 2011-08-25 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
EP3248615A1 (en) 2010-03-30 2017-11-29 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
JP2013529913A (en) 2010-06-02 2013-07-25 アヴィール グリーン ヒルズ バイオテクノロジー リサーチ ディベロプメント トレード アクチエンゲゼルシャフト Method for the preparation of RNA viruses and helper viruses
AR083533A1 (en) 2010-10-22 2013-03-06 Boehringer Ingelheim Vetmed PROTEINS OF HEMAGLUTININ 5 (H5) FOR THE TREATMENT AND PREVENTION OF INFLECTIONS OF FLU
EP4024029A3 (en) 2011-01-21 2022-09-14 Labrador Diagnostics LLC Systems and methods for sample use maximization
CN103403159B (en) * 2011-02-08 2018-09-14 国立大学法人三重大学 The manufacturing method of viral vectors for channel genes
US20130189303A1 (en) 2011-08-02 2013-07-25 Yan Zhou Recombinant swine influenza virus and uses thereof
AR088028A1 (en) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed PROTEINS H5, FROM H5N1 FOR MEDICINAL USE
ES2655051T3 (en) 2011-08-26 2018-02-16 Wisconsin Alumni Research Foundation Influenza virus with mutant PB2 gene segment as live attenuated vaccines
US8475739B2 (en) 2011-09-25 2013-07-02 Theranos, Inc. Systems and methods for fluid handling
US20140170735A1 (en) 2011-09-25 2014-06-19 Elizabeth A. Holmes Systems and methods for multi-analysis
US9664702B2 (en) 2011-09-25 2017-05-30 Theranos, Inc. Fluid handling apparatus and configurations
US9632102B2 (en) 2011-09-25 2017-04-25 Theranos, Inc. Systems and methods for multi-purpose analysis
IN2014CN02114A (en) 2011-09-20 2015-05-29 Sinai School Medicine
US9810704B2 (en) 2013-02-18 2017-11-07 Theranos, Inc. Systems and methods for multi-analysis
US10012664B2 (en) 2011-09-25 2018-07-03 Theranos Ip Company, Llc Systems and methods for fluid and component handling
US9017694B2 (en) 2011-10-07 2015-04-28 Medimmune, Llc Swine influenza hemagglutinin variants
CA2852857A1 (en) 2011-10-20 2013-04-25 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
US9982240B2 (en) 2012-08-03 2018-05-29 Sanofi Pasteur Production of infectious influenza viruses
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
EA201591164A1 (en) 2012-12-18 2015-11-30 Икан Скул Оф Медсин Эт Маунт Синай VACCINES AGAINST FLU VIRUS AND THEIR USE
US10401373B1 (en) 2013-02-18 2019-09-03 Theranos Ip Company, Llc Systems and methods for analyte testing and laboratory oversight
US11008628B1 (en) 2013-02-18 2021-05-18 Labrador Diagnostics Llc Systems and methods for analyte testing and laboratory oversight
WO2014127825A1 (en) 2013-02-21 2014-08-28 Boehringer Ingelheim Vetmedica Gmbh H5 proteins of h5n1 influenza virus for use as a medicament
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
US9950057B2 (en) 2013-07-15 2018-04-24 Wisconsin Alumni Research Foundation (Warf) High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs
US10422806B1 (en) 2013-07-25 2019-09-24 Theranos Ip Company, Llc Methods for improving assays of biological samples
DK3080274T3 (en) 2013-12-09 2020-08-31 Sangamo Therapeutics Inc Methods and compositions for genome manipulation
CN103757032B (en) * 2014-01-28 2017-06-06 中国人民解放军第三0二医院 A kind of HCV chimerics with influenza virus as carrier and preparation method thereof
AU2015218576B2 (en) 2014-02-24 2020-02-27 Sangamo Therapeutics, Inc. Methods and compositions for nuclease-mediated targeted integration
US11360107B1 (en) 2014-02-25 2022-06-14 Labrador Diagnostics Llc Systems and methods for sample handling
CN106459894B (en) 2014-03-18 2020-02-18 桑格摩生物科学股份有限公司 Methods and compositions for modulating zinc finger protein expression
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
MA40772A (en) * 2014-10-02 2017-08-08 Vertex Pharma INFLUENZA A VIRUS VARIANTS
MA40773A (en) * 2014-10-02 2017-08-08 Vertex Pharma INFLUENZA A VIRUS VARIANTS
CN104450695B (en) * 2014-11-26 2017-08-25 扬州大学 Influenza A gene PCR amplimer and its rapid clon method
US10889834B2 (en) 2014-12-15 2021-01-12 Sangamo Therapeutics, Inc. Methods and compositions for enhancing targeted transgene integration
EP3247389A4 (en) 2015-01-23 2019-10-30 Icahn School of Medicine at Mount Sinai VACCINATION REGIMES FOR INFLUENZA VIRUSES
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
WO2016201127A1 (en) 2015-06-09 2016-12-15 Sanofi Pasteur, Inc. Methods of optimizing nucleotide sequences encoding engineered influenza proteins
HK1254344A1 (en) 2015-06-26 2019-07-19 Seqirus UK Limited Antigenically matched influenza vaccines
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
HUE051783T2 (en) 2015-07-07 2021-03-29 Seqirus Uk Ltd Method for quantifying immunogenic hemagglutinin
JP6624736B2 (en) * 2015-11-18 2019-12-25 国立研究開発法人農業・食品産業技術総合研究機構 Influenza virus analyzer, influenza virus analysis method, and influenza virus analysis program
CA3014435C (en) 2016-02-19 2023-04-18 Wisconsin Alumni Research Foundation (Warf) Improved influenza b virus replication for vaccine development
US10844097B2 (en) 2016-06-02 2020-11-24 Sanofi Pasteur Inc. Engineered influenza antigenic polypeptides and immunogenic compositions thereof
CA3023143A1 (en) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
EA201991319A1 (en) 2016-11-30 2019-11-29 VACCINES OF ATTENUATED SWINE INFLUENZA AND METHODS OF THEIR MANUFACTURE AND APPLICATION
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
WO2019084310A1 (en) 2017-10-25 2019-05-02 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs
MX2020004151A (en) 2017-10-30 2020-08-13 Takeda Pharmaceuticals Co Environmentally compatible detergents for inactivation of lipid-enveloped viruses.
EP3810634A4 (en) 2018-06-21 2022-07-27 Icahn School of Medicine at Mount Sinai INFLUENZA MOSAIC VIRUS HEMAGGLUTININ POLYPEPTIDES AND THEIR USES
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
JP7655849B2 (en) 2018-08-20 2025-04-02 ウィスコンシン アルムニ リサーチ ファンデイション Vectors for eliciting immune responses against non-dominant epitopes within the hemagglutinin (HA) protein
US11241492B2 (en) 2019-01-23 2022-02-08 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to genes in influenza viruses
WO2020163804A1 (en) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
EP3959216A4 (en) 2019-04-24 2023-01-11 Icahn School of Medicine at Mount Sinai ANTI-NEURAMINIDASE ANTIBODIES TO INFLUENZA TYPE B VIRUS AND THEIR USES
US11390649B2 (en) 2019-05-01 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
WO2021150874A1 (en) 2020-01-24 2021-07-29 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized na
US12290562B2 (en) 2020-03-25 2025-05-06 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
CN116134137A (en) 2020-07-21 2023-05-16 复尔健有限公司 Influenza virus backbone
US12569550B2 (en) * 2020-09-02 2026-03-10 St. Jude Children's Research Hospital, Inc. Hemagglutinin modifications for improved influenza vaccine production
AU2021342299A1 (en) * 2020-09-11 2023-04-13 The United States Of America, As Represented By The Secretary Of Agriculture Compositions and methods of use thereof for prevention and treatment of influenza infections
KR102614346B1 (en) 2020-12-14 2023-12-14 서울대학교산학협력단 H5N6 recombinant influenza virus, a composition for preparing the same, and a vaccine composition containing the same
CN121039284A (en) 2023-03-22 2025-11-28 兰蒂迪克有限公司 Expression builder
WO2025019631A1 (en) 2023-07-19 2025-01-23 Icahn School Of Medicine At Mount Sinai Immunogenic compositions containing inactivated influenza a virus and cpg oligonucleotide adjuvant and uses thereof
WO2025072889A1 (en) * 2023-09-28 2025-04-03 E & E Bioclub Llc Helper-free rescue system for negative-strand rna viruses
WO2025075855A1 (en) * 2023-10-03 2025-04-10 St. Jude Children's Research Hospital, Inc. Reverse genetics vector and associated method of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992522A (en) * 1973-01-24 1976-11-16 The United States Of America As Represented By The Department Of Health, Education And Welfare Temperature-sensitive recombinant mutant viruses and a process for producing same
WO1991003552A1 (en) * 1989-08-28 1991-03-21 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression systems and vaccines

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854037A (en) * 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5786199A (en) * 1989-08-28 1998-07-28 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5840520A (en) * 1989-08-28 1998-11-24 Aviron Recombinant negative strand RNA virus expression systems
EP0808361A4 (en) 1994-11-16 2001-07-18 St Jude Childrens Res Hospital NEW REPLICATION PROCESS
EP1820853B1 (en) 1999-04-06 2011-09-21 Wisconsin Alumni Research Foundation Recombinant influenza viruses for vaccines and gene therapy
MXPA02010642A (en) * 2000-04-28 2004-05-17 St Jude Children S Res Hospital Dna transfection system for the generation of infectious influenza virus.
US7465456B2 (en) * 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
ES2526191T3 (en) * 2002-04-26 2015-01-08 Medimmune, Llc Method to produce infectious influenza B virus in cell culture
ATE469972T1 (en) * 2003-12-23 2010-06-15 Medimmune Llc MULTIPLASMID SYSTEM FOR GENERATING THE FLU VIRUS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992522A (en) * 1973-01-24 1976-11-16 The United States Of America As Represented By The Department Of Health, Education And Welfare Temperature-sensitive recombinant mutant viruses and a process for producing same
WO1991003552A1 (en) * 1989-08-28 1991-03-21 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression systems and vaccines

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HOFFMANN E ET AL: ""Ambisense" approach for the generation of influenza A virus: vRNA and mRNA synthesis from one template.", VIROLOGY. UNITED STATES 15 FEB 2000, vol. 267, no. 2, 15 February 2000 (2000-02-15), pages 310 - 317, XP002223258, ISSN: 0042-6822 *
HOFFMANN E ET AL: "Characterization of the influenza A virus gene pool in avian species in southern China: was H6N1 a derivative or a precursor of H5N1?", JOURNAL OF VIROLOGY. UNITED STATES JUL 2000, vol. 74, no. 14, July 2000 (2000-07-01), pages 6309 - 6315, XP002223261, ISSN: 0022-538X *
HOFFMANN ERICH ET AL: "Unidirectional RNA polymerase I-polymerase II transcription system for the generation of influenza A virus from eight plasmids.", JOURNAL OF GENERAL VIROLOGY, vol. 81, no. 12, December 2000 (2000-12-01), pages 2843 - 2847, XP002223259, ISSN: 0022-1317 *
NEUMANN GABRIELE ET AL: "Generation of influenza A viruses entirely from cloned cDNAs.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 96, no. 16, 3 August 1999 (1999-08-03), Aug. 3, 1999, pages 9345 - 9350, XP002223260, ISSN: 0027-8424 *
PALESE P ET AL: "NEGATIVE-STRAND RNA VIRUSES: GENETIC ENGINEERING AND APPLICATIONS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 93, 1 October 1996 (1996-10-01), pages 11350 - 11354, XP000196755, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
US20110250232A1 (en) 2011-10-13
EP1317559A2 (en) 2003-06-11
NZ521840A (en) 2004-11-26
IL152426A (en) 2011-07-31
DE60137345D1 (en) 2009-02-26
EP1317559B1 (en) 2009-01-07
BR0110607A (en) 2004-06-22
ZA200208065B (en) 2003-11-12
US7972843B2 (en) 2011-07-05
HU229101B1 (en) 2013-07-29
NO20025171D0 (en) 2002-10-28
NO20025171L (en) 2002-12-30
ATE420189T1 (en) 2009-01-15
CA2406100C (en) 2010-11-02
AU5921101A (en) 2001-11-12
US20080233560A1 (en) 2008-09-25
BRPI0110607B1 (en) 2020-08-11
ES2319864T3 (en) 2009-05-14
AU2006228054B2 (en) 2010-04-29
US8309099B2 (en) 2012-11-13
KR20030072209A (en) 2003-09-13
HK1055992A1 (en) 2004-01-30
KR100862758B1 (en) 2008-10-13
EA200201164A1 (en) 2003-10-30
CN101580849A (en) 2009-11-18
AU2006228054A1 (en) 2006-11-02
KR100848719B1 (en) 2008-07-25
US6951754B2 (en) 2005-10-04
CN101580849B (en) 2012-11-21
UA84254C2 (en) 2008-10-10
CA2406100A1 (en) 2001-11-08
PL205955B1 (en) 2010-06-30
WO2001083794A2 (en) 2001-11-08
HUP0303036A2 (en) 2003-12-29
US20080311148A1 (en) 2008-12-18
AU2001259211B2 (en) 2006-07-13
BRPI0110607B8 (en) 2021-05-25
JP2013116112A (en) 2013-06-13
CN100489107C (en) 2009-05-20
JP2010042030A (en) 2010-02-25
US20050186563A1 (en) 2005-08-25
SI1317559T1 (en) 2009-04-30
PL366064A1 (en) 2005-01-24
HUP0303036A3 (en) 2004-10-28
DK1317559T3 (en) 2009-03-23
KR20070086094A (en) 2007-08-27
PT1317559E (en) 2009-02-12
MXPA02010642A (en) 2004-05-17
EP2085468A1 (en) 2009-08-05
CY1108735T1 (en) 2014-04-09
US7312064B2 (en) 2007-12-25
EA006311B1 (en) 2005-10-27
US20080311149A1 (en) 2008-12-18
DE122011100039I1 (en) 2011-12-08
US20020164770A1 (en) 2002-11-07
JP2004500842A (en) 2004-01-15
CN1856575A (en) 2006-11-01
IL152426A0 (en) 2003-05-29
NO332080B1 (en) 2012-06-18
JP5837891B2 (en) 2015-12-24
JP5745758B2 (en) 2015-07-08

Similar Documents

Publication Publication Date Title
WO2001083794A3 (en) Dna transfection system for the generation of infectious influenza virus
Berglund et al. Enhancing immune responses using suicidal DNA vaccines
Lauer et al. Multivalent and multipathogen viral vector vaccines
EP1270016A4 (en) AIDS VIRUS VACCINE USING A SENDAIVIRUS VECTOR
Vemula et al. Production of adenovirus vectors and their use as a delivery system for influenza vaccines
Liu et al. Virus like particle-based vaccines against emerging infectious disease viruses
Sun et al. The status and prospects of Epstein–Barr virus prophylactic vaccine development
Rajčáni et al. Current developments in viral DNA vaccines: shall they solve the unsolved?
Ma et al. Swine influenza vaccines: current status and future perspectives
JP2004500842A5 (en)
JP2011504486A5 (en)
Palese et al. Development of novel influenza virus vaccines and vectors
AU2002337083A1 (en) Vaccinia virus mva-e3l-knockout-mutants and use thereof
Tang et al. Recombinant adenoviruses displaying matrix 2 ectodomain epitopes on their fiber proteins as universal influenza vaccines
EP1427443A4 (en) VACCINE USING VIRUS VIRUS-ADJUSTED PAPILLOMA VIRUS PROTEINS
Ding et al. Superior neutralizing antibody response and protection in mice vaccinated with heterologous DNA prime and virus like particle boost against HPAI H5N1 virus
Goulding et al. OX40: OX40L axis: emerging targets for improving poxvirus‐based CD8+ T‐cell vaccines against respiratory viruses
WO2005117961A1 (en) Sars virus vaccine with adenovirus carrier and preparation method thereof , and use of sars virus s gene for preparation of vaccine
WO1999057284A3 (en) Attenuated influenza viruses
WO2001055330A3 (en) Recombinant rhabdoviruses as live-viral vaccines for immunodeficiency viruses
Xiao et al. A replicating modified vaccinia tiantan strain expressing an avian-derived influenza H5N1 hemagglutinin induce broadly neutralizing antibodies and cross-clade protective immunity in mice
Dulin et al. Harnessing preexisting influenza virus-specific immunity increases antibody responses against SARS-CoV-2
WO2022191801A3 (en) Integrase defective hiv-based lentivirus mediated new generation covid-19 vaccine encoding sars-cov-2 spike protein
Federico Virus-like particles show promise as candidates for new vaccine strategies
Das et al. ADVANCING VACCINE DEVELOPMENT AND DELIVERY: THE ROLE OF GENETIC ENGINEERING

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 521840

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002/08065

Country of ref document: ZA

Ref document number: 200208065

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2001259211

Country of ref document: AU

Ref document number: 2406100

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/01440/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 152426

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2001 580401

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020027014311

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/010642

Country of ref document: MX

Ref document number: 2001932704

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 018101739

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 200201164

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2001932704

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020027014311

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 521840

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 521840

Country of ref document: NZ